← back to search

Carlo Tondini

Vall d'Hebron Hospital Universitari · IT
Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, BRCA gene mutations in cancer, and COVID-19 and healthcare impacts.
h-index
47
citations
12,751
works
241
NIH funding
primary concept
Medicine
email

Recent publications

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
JAMA Oncology 2024cited by 10position: middledoi
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry
Therapeutic Advances in Medical Oncology 2024cited by 1position: middledoi
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Annals of Oncology 2023cited by 44position: middledoi
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
European Journal of Cancer 2023cited by 12position: middledoi
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2023cited by 0position: contributordoi
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2023cited by 0position: contributordoi
Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2023cited by 0position: contributordoi
Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2023cited by 0position: contributordoi
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Journal of Clinical Oncology 2022cited by 148position: middledoi
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial.
2022cited by 5position: contributordoi
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
The Lancet Oncology 2021cited by 136position: middledoi
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Annals of Oncology 2021cited by 86position: middledoi
Time-Dependent COVID-19 Mortality in Patients With Cancer
JAMA Oncology 2021cited by 72position: middledoi
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Journal for ImmunoTherapy of Cancer 2021cited by 62position: middledoi
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study
European Journal of Cancer 2021cited by 51position: middledoi
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Journal for ImmunoTherapy of Cancer 2021cited by 41position: middledoi
Multigene tests for breast cancer: the physician’s perspective
Oncotarget 2021cited by 18position: middledoi
The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model.
2021cited by 5position: contributordoi
Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study
UCL Discovery (University College London) 2021cited by 0position: middle
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial (Preprint)
2021cited by 0position: contributordoi
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
2020cited by 157position: contributordoi
Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.
Journal of Clinical Oncology 2020cited by 30position: middledoi
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families
Journal of Clinical Oncology 2019cited by 409position: middledoi
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Journal of Clinical Oncology 2019cited by 147position: middledoi
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Annals of Oncology 2019cited by 113position: middledoi
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
2019cited by 76position: contributordoi
Homologous recombination DNA repair defects in PALB2-associated breast cancers
npj Breast Cancer 2019cited by 57position: middledoi
The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries
Human Mutation 2019cited by 48position: middledoi
Homologous recombination DNA repair defects in <i>PALB2-</i>associated breast cancers.
2019cited by 44position: contributordoi
The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries.
2019cited by 39position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 8 papers (2020–2023)Isabel Ruíz-Camps · Instituto de Radioastronomía Milimétrica5 papers (2020–2023)Alba Cabirta · Hebron University5 papers (2020–2023)Lorenza Rimassa · IRCCS Humanitas Research Hospital5 papers (2020–2023) · 5 papers (2020–2023) · 5 papers (2020–2023)Mark Bower · Fondazione IRCCS Istituto Nazionale dei Tumori5 papers (2020–2023)Gianluca Gaidano · Elsevier, Inc.5 papers (2020–2023) · 5 papers (2020–2023)Isabel Garcia-Fructuoso · Breast Cancer Research Foundation5 papers (2020–2023) · 5 papers (2020–2023) · 5 papers (2020–2023)Joan Brunet · Hôpitaux Universitaires de Strasbourg5 papers (2020–2023) · 5 papers (2020–2023) · 5 papers (2020–2023) · 5 papers (2020–2023)Andrea Patriarca · Ospedale Maggiore5 papers (2020–2023)Alberto Zambelli · Istituti di Ricovero e Cura a Carattere Scientifico4 papers (2019–2022)Marco Colleoni · European Institute of Oncology3 papers (2015–2019)Olivia Pagani · Hôpital Riviera-Chablais3 papers (2015–2019)